About ixabepilone
Epothilone antineoplastic agent
Used for
- Advanced or metastatic breast cancer after other treatments have failed.
- Used alone or with capecitabine in selected patients.
Usual adult dose
40 mg/m² by intravenous infusion over three hours every three weeks; dose may be adjusted.
Common side effects
- Low blood cell counts, increasing infection or bleeding risk.
- Fatigue, weakness, or fever.
- Nausea, vomiting, diarrhea, or constipation.
- Peripheral neuropathy, muscle or joint pain, or hair loss.
Important warnings
- Can cause severe bone marrow suppression and serious infections.
- Can cause severe allergic reactions; premedication is generally required.
- May cause or worsen peripheral neuropathy; treatment may need adjustment.
- Avoid in significant liver impairment; combination with capecitabine has additional restrictions.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for a period afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least three weeks after the last dose.
Interactions
- Strong CYP3A4 inhibitors can increase ixabepilone exposure.
- Strong CYP3A4 inducers can reduce ixabepilone exposure.
- Grapefruit may affect CYP3A4 and should be avoided.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.